Every Form 4 that MINIMED GROUP INC (MMED) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow MMED and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full MMED filings page.
MiniMed Group, Inc. executive Courtney Nelson, SVP, General Counsel and Corporate Secretary, reported a tax-withholding disposition of 1,762 shares of common stock on July 31, 2026, at $18.15 per share. The shares were withheld to cover income taxes on vesting RSUs, leaving 136,384 shares held directly, including shares issuable from RSUs.
MiniMed Group, Inc. executive Dianaty Ali, EVP Ch. Prod. & Tech Officer, reported a tax-withholding disposition of 8,012 shares of Common Stock on July 31, 2026, at $18.15 per share to cover income tax obligations from RSU vesting. After this transaction, Ali directly holds 315,158 shares, including shares to be issued upon RSU vesting.
Dallara Que, Chief Executive Officer of MiniMed Group, Inc., reported a tax-withholding disposition of 31,350 shares of Common Stock on July 31, 2026 at $18.15 per share. The shares were withheld by the company to satisfy RSU-related tax obligations. Que now directly holds 884,749 shares, including shares issuable upon RSU vesting.
MiniMed Group, Inc. EVP and Chief Financial Officer Chad Spooner reported a tax-withholding disposition of 23,301 shares of Common Stock on July 28, 2026. These shares were withheld by MiniMed Group to satisfy income tax withholding and remittance obligations tied to vesting Restricted Stock Units. After this withholding, Spooner directly holds 362,707 shares of Common Stock, including shares to be issued upon the vesting of one or more RSUs.
MiniMed Group, Inc. executive Chandrasena Gillian, SVP and Chief HR Officer, reported a tax-withholding disposition of 2,099 shares of Common Stock on 2026-07-28 at $17.67 per share. The shares were withheld by the company to satisfy income tax obligations related to RSU vesting, leaving 172,745 shares owned directly, including shares to be issued upon the vesting of one or more RSUs.
MiniMed Group, Inc. senior vice president and general counsel Courtney Nelson reported equity compensation grants of common stock on July 1, 2026. The Form 4 shows two awards totaling 22,057 and 60,730 shares, each recorded at $0.00 per share as compensation rather than open-market purchases.
Footnotes state these represent restricted stock units granted under the 2026 Long Term Incentive Plan. One grant vests in roughly equal one-third installments on the first, second and third anniversaries of the grant date, while the other vests on the third anniversary. Following these awards, the filing reports updated direct holdings of 138,146 and 116,089 common shares in the respective lines, including shares issuable upon RSU vesting and 296 shares acquired via the 2026 Employee Stock Purchase Plan.
MiniMed Group, Inc. executive Gyurci John, VP and Chief Accounting Officer, reported an equity compensation grant rather than a market purchase or sale. He received 24,244 shares of Common Stock as a grant of restricted stock units under the 2026 Long Term Incentive Plan, with these RSUs vesting in approximately equal one-third increments on the first, second and third anniversaries of the grant date. Following this award, his directly held position is reported as 39,941 shares of common stock, which includes shares issuable upon vesting of one or more RSUs and 375 shares acquired through MiniMed’s 2026 Employee Stock Purchase Plan.
MiniMed Group, Inc. senior vice president and chief HR officer Gillian Chandrasena reported two equity compensation grants of common stock on July 1, 2026. Both transactions are coded as awards, not open‑market purchases or sales.
The filing shows one grant of 14,705 restricted stock units (RSUs) under the 2026 Long Term Incentive Plan that vest in approximately equal one‑third increments on the first, second and third anniversaries of the grant date. A second RSU grant of 29,483 shares vests on the third anniversary of the grant date. Following these awards, reported direct holdings include common stock and shares that will be issued as RSUs vest, as well as 891 shares acquired under the 2026 Employee Stock Purchase Plan on June 30, 2026.
Spooner Chad reported acquisition or exercise transactions in this Form 4 filing.
MiniMed Group, Inc. reported that EVP and Chief Financial Officer Chad Spooner received equity-based compensation in the form of restricted stock units tied to common stock. He was granted 22,057 shares that vest in three equal annual installments and 94,550 shares that vest on the third anniversary of the grant date.
Both awards were granted at no cash cost per share and are part of the 2026 MiniMed Group, Inc. Long Term Incentive Plan. Following these grants, Spooner directly holds more than 360,000 shares of common stock, indicating this is a compensation-related increase rather than an open-market purchase.
MiniMed Group, Inc. reported that officer Ali Dianaty received two equity awards of common stock on July 1, 2026. The filing shows grants classified as restricted stock units under the 2026 Long Term Incentive Plan, covering 36,762 shares and 94,550 shares of common stock at no cash cost.
The RSUs tied to these awards vest over time, with one grant vesting in approximately equal one-third increments on the first, second and third anniversaries of the grant date, and another vesting on the third anniversary. Existing holdings also include shares to be issued upon vesting of prior RSUs and 600 shares acquired under the 2026 Employee Stock Purchase Plan.
MiniMed Group, Inc. reported that Chief Executive Officer Dallara Que received a grant of 297,618 restricted stock units (RSUs) of common stock at no cost, described as a grant, award or other acquisition under the company’s 2026 Long Term Incentive Plan.
The RSUs vest in approximately equal one-third increments on the first, second and third anniversaries of the grant date, tying most of the benefit to future service and performance. Following this award, Que holds 916,099 shares of common stock, including shares expected to be issued upon vesting of one or more RSUs and 1,727 shares acquired through the 2026 Employee Stock Purchase Plan.
MiniMed Group, Inc. Chief Executive Officer Dallara Que reported a routine tax-related share disposition. On this Form 4, 4,809 shares of Common Stock were withheld by the company at $16.31 per share to cover income tax obligations tied to vesting RSUs. After this withholding, Que directly holds 616,754 shares, and the filing notes that this total includes shares to be issued upon future RSU vesting.
MiniMed Group, Inc. officer John Gyurci reported receiving 15,322 shares of common stock on a grant or award basis, with no cash price per share. These shares represent restricted stock units in MiniMed that were created by converting prior Medtronic equity awards in connection with MiniMed’s separation from Medtronic.
The units were granted under the 2026 MiniMed Group, Inc. Long Term Incentive Plan and vest in three equal installments on January 26, 2027, January 26, 2028, and January 26, 2029. Following this equity award conversion, Gyurci directly holds 15,322 MiniMed shares, including shares to be issued upon future vesting of restricted stock units.
MiniMed Group, Inc. insider Chandrasena Gillian reported multiple grants of common stock on March 11, 2026, all classified as awards rather than market purchases. Each grant reflects MMED restricted stock units received at a price of $0.00 per share.
According to the footnotes, these MMED RSUs were issued when certain Medtronic plc equity awards held by the insider were converted into MiniMed awards in connection with the company’s separation from Medtronic effective March 9, 2026, under the 2026 MiniMed Group, Inc. Long Term Incentive Plan. The converted RSUs vest over time, with tranches scheduled between July 28, 2026 and July 28, 2028, making this a compensation-related equity conversion, not an open‑market stock trade.
MiniMed Group, Inc. reported a compensation-related stock grant to officer Wills Courtney Nelson tied to the company’s separation from Medtronic. On March 11, 2026, Nelson received several awards of MiniMed common stock as part of the conversion of prior Medtronic equity awards into MiniMed restricted stock units under the 2026 Long Term Incentive Plan.
The awards were granted at $0.00 per share and represent time-vesting RSUs that will settle in MiniMed shares as they vest. According to the footnotes, these RSUs result from an equity award conversion process using average trading prices of both Medtronic and MiniMed shares, with vesting dates ranging from July 31, 2026 through April 28, 2028.
MiniMed Group, Inc. reported that officer Dianaty Ali received multiple grants of common stock on March 11, 2026, all with a grant price of $0.00 per share. These are classified as awards rather than open-market purchases.
The grants represent MMED restricted stock units created when prior Medtronic restricted and performance share awards were converted following MiniMed’s separation from Medtronic effective March 9, 2026, under an Employee Matters Agreement. The MMED RSUs were issued under the 2026 MiniMed Group, Inc. Long Term Incentive Plan and vest on several dates between July 31, 2026 and October 29, 2028, including single-date vesting and a three-installment schedule.
MiniMed Group, Inc. EVP and Chief Financial Officer Chad Spooner received multiple equity awards in connection with MiniMed’s separation from Medtronic plc. On March 11, 2026, he was granted time-vesting restricted stock units (MMED RSUs) that were created by converting prior Medtronic restricted stock and performance share awards under an Employee Matters Agreement tied to the March 9, 2026 separation.
The grants cover 70,896 shares vesting on April 28, 2028, 127,609 shares vesting in three equal installments on July 28, 2026, July 28, 2027 and July 28, 2028, and 70,896 shares vesting on July 28, 2028. All awards were issued at a reported price of $0.00 per share as compensation, not as open-market purchases or sales, and were made under the 2026 MiniMed Group, Inc. Long Term Incentive Plan.
MiniMed Group, Inc. reported that Chief Executive Officer Dallara Que received multiple equity awards in the form of MiniMed common stock–denominated restricted stock units on March 11, 2026. These awards were granted at a price of $0.00 per share as compensation, not through open-market purchases.
The footnotes explain that existing Medtronic restricted stock units and performance share units held by Que were converted into MiniMed RSUs in connection with MiniMed’s separation from Medtronic plc, under an Employee Matters Agreement. The converted RSUs were issued under the 2026 MiniMed Group, Inc. Long Term Incentive Plan and vest on various dates between July 31, 2026 and April 28, 2028, with one grant vesting in two installments on March 10, 2026 and March 10, 2027.
MiniMed Group, Inc. director Timothy A. Wicks reported an acquisition of 13,889 shares of common stock through a grant of restricted stock units. These units vest on the one-year anniversary of the grant date rather than being immediately transferable.
After this award, Wicks is shown as directly holding 13,889 shares, which include shares to be issued upon the future vesting of one or more restricted stock units. The transaction reflects equity-based compensation rather than an open-market purchase.
MiniMed Group, Inc. director D Keith Grossman reported an equity compensation grant of 13,889 shares of Common Stock on March 9, 2026. The award consists of restricted stock units that vest on the one-year anniversary of the grant date and were granted at no cash cost to him.
Following this grant, Grossman holds 13,889 shares of Common Stock directly, including shares that will be issued upon vesting of one or more restricted stock units. This filing reflects a compensation-related acquisition rather than an open-market stock purchase.
EISENBERG GLENN A reported acquisition or exercise transactions in this Form 4 filing.
MiniMed Group, Inc. director Glenn A. Eisenberg received an equity grant of 13,889 shares of common stock in the form of restricted stock units. The units were awarded at no cash cost and vest on the one-year anniversary of the grant date. Following this award, he directly holds 13,889 shares and units, including shares to be issued upon future vesting of restricted stock units.
MiniMed Group, Inc. director Kevin E. Lofton reported an equity compensation grant of 27,778 shares of Common Stock in the form of restricted stock units. The award was granted at no cash cost per share and is scheduled to vest on the one-year anniversary of the grant date.
After this grant, Lofton is shown as owning 27,778 shares directly, which include shares to be issued upon future vesting of one or more restricted stock units. This filing reflects a routine compensation-related acquisition rather than an open-market purchase or sale.
MiniMed Group, Inc. officer John Gyurci reported equity compensation grants on March 9, 2026. He received 2,778 performance-based restricted stock units, each tied to one share of common stock, which vest on March 9, 2027 only if MMED’s closing price reaches at least $32.05 as of the Divestment Date defined in a March 1, 2026 separation agreement. He was also granted options on 25,253 shares of common stock at an exercise price of $18.00 per share, expiring on March 9, 2036, vesting 33% on each of March 9, 2028 and March 9, 2029, and 34% on March 9, 2030.
MiniMed Group, Inc. officer Chandrasena Gillian reported compensation-related equity awards, not open-market trades. She received 6,945 performance-based restricted stock units, each representing a right to one MMED common share, which vest on March 9, 2027 if MMED’s closing share price is at least $32.05 as of the defined Divestment Date.
She also received employee stock options for 63,132 MMED common shares at an exercise price of $18.00 per share, expiring in 2036. These options vest 33% on March 9, 2028, 33% on March 9, 2029, and 34% on March 9, 2030. All holdings reported are owned directly.
MiniMed Group, Inc. insider Courtney Nelson received new equity awards as compensation. On March 9, 2026, Nelson was granted 6,945 performance-based restricted stock units, each tied to one share of MMED common stock. These units vest on March 9, 2027 if MMED’s closing share price reaches at least $32.05 as of the Divestment Date defined in a March 1, 2026 separation agreement.
On the same date, Nelson also received an option to purchase 63,132 shares of MMED common stock at an exercise price of $18.00 per share, expiring March 9, 2036. This option vests 33% on March 9, 2028, 33% on March 9, 2029, and 34% on March 9, 2030. All awards are reported as directly owned and are grants, not open-market purchases or sales.
MiniMed Group, Inc. reported that officer Ali Dianaty received equity-based compensation. On March 9, 2026, Dianaty was granted 13,889 performance-based RSUs, each tied to one share of MMED common stock and vesting around March 9, 2027 based on share-price performance and a divestment-related date defined in a March 1, 2026 separation agreement. On the same date, Dianaty also received 126,263 stock options with a $18.00 exercise price, expiring in 2036, vesting 33% on each of March 9, 2028 and March 9, 2029, and 34% on March 9, 2030. All holdings reported are direct and reflect compensation grants rather than open-market purchases or sales.
MiniMed Group, Inc. reported that EVP and Chief Financial Officer Chad Spooner received new equity awards. He was granted 27,778 performance-based restricted stock units, each representing one share of common stock, vesting on March 9, 2027, if MiniMed’s share price reaches at least $32.05 as of the Divestment Date. He also received options for 84,176 shares of common stock at an exercise price of $18.00 per share, vesting 33% on March 9, 2028, 33% on March 9, 2029, and 34% on March 9, 2030, with expiration on March 9, 2036.
MiniMed Group, Inc. Chief Executive Officer Dallara Que reported awards of new equity-based compensation. On March 9, 2026, Que received 83,334 performance-based restricted stock units, each representing a contingent right to one share of MiniMed common stock. These units vest on March 9, 2027 if MiniMed’s common stock closes at or above $32.05 per share as of the defined Divestment Date.
On the same date, Que also received 252,526 employee stock options with an exercise price of $18.00 per share and expiration on March 9, 2036. These options vest in tranches of 33% on each of March 9, 2028 and March 9, 2029, and 34% on March 9, 2030, providing a long-term incentive structure tied to future service and share price performance.